Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ...

On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly. He knocked $110 per share off his price target for a new fair-value assessment of $900 per share, while maintaining ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Bernstein Senior Analyst, US Biopharmaceuticals Courtney ... industry and painted the order as a blow against drugmakers. Eli Lilly (NYSE:LLY) recently announced the impressive results of its ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on ...

While arch rival Eli Lilly and Company ... a step function change for Lilly’s market leadership over NVO and its peers. Lilly management provided insights into the advantages of why the ...

Down but far from out On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly. He knocked $110 per share off his price target for a new fair-value assessment of $900 per ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...